更新于：2024-05-08
Dalbavancin Hydrochloride
盐酸达巴万星
更新于：2024-05-08
概要
基本信息
药物类型 化学药 |
别名 dalbavancin、dalbavancin hcl、Dalvance + [11] |
作用机制 肽聚糖抑制剂、细胞壁抑制剂 |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2014-05-23), |
最高研发阶段(中国)无进展 |
特殊审评快速通道 (美国)、孤儿药 (美国) |
登录后查看首次获批时间轴
关联
40
项与 盐酸达巴万星 相关的临床试验Prevention and Treatment of Frostbite Infection With Antimicrobial Pharmacokinetic Analysis
Randomized Open-label Controlled Trial Evaluating a Single-dose Intravenous Dalbavancin Versus Standard Antibiotic Therapy During Catheter-related Bloodstream Infections Due to Staphylococcus Aureus
An Open-label, Pilot Clinical Trial of Dalbavancin for the Treatment of Susceptible Gram-positive Infections Requiring Prolonged Intravenous Antibiotic Therapy
100 项与 盐酸达巴万星 相关的临床结果
登录后查看更多信息
100 项与 盐酸达巴万星 相关的转化医学
登录后查看更多信息
100 项与 盐酸达巴万星 相关的专利（医药）
登录后查看更多信息
697
项与 盐酸达巴万星 相关的文献（医药）2024-03-01Journal of Global Antimicrobial Resistance
Dalbavancin real-life utilization among diabetic patients suffering from infections in Italy and Spain: The DALBADIA retrospective cohort study
Article
作者: Cattaneo, Agnese ; Gentile, Ivan ; De Rosa, Francesco Giuseppe ; Grossi, Paolo Antonio ; Morata Ruiz, Laura ; Comandini, Alessandro ; Ruggieri, Alessandro ; Moreno Núñez, Leonor ; Falcone, Marco ; Salavert Lletí, Miguel ; Cascio, Antonio ; Pasquau Liaño, Juan ; Ori, Alessandra ; Tascini, Carlo ; Loeches Yagüe, Maria
OBJECTIVES:
To retrospectively describe the patterns of use of dalbavancin for treating infections in diabetic patients in Italian and Spanish standard clinical practice.
METHODS:
DALBADIA [NCT04959799] was a multicentre, observational, retrospective cohort study, conducted in Italy and Spain. The study enrolled 97 adults with type 1 or 2 diabetes mellitus, treated with dalbavancin as per standard clinical practice for a Gram-positive bacterial infection or the Gram-positive component of a mixed infection.
RESULTS:
Dalbavancin was used to treat cellulitis (18/92 patients, 19.6%), followed by prosthetic joint infection (14 patients, 15.2%), endocarditis (13 patients, 14.1%), and primary bacteraemia (10 patients, 10.9%); 78/92 (84.8%) patients had Gram-positive infections only, and 14 (15.2%) had mixed infections. The most frequently isolated microorganisms were Staphylococcus aureus in 43 (55.8% of the patients with microbial isolation), 25.6% of which methicillin-resistant; Staphylococcus epidermidis in 13 (16.9%), 53.8% of which methicillin-resistant; Enterococcus faecalis in 11 (14.3%). The main reason for the dalbavancin choice was the intent to simplify the antibiotic regimen (81.5% of cases). A multidisciplinary team participated in the treatment choice process for 53 (57.6%) patients. Dalbavancin was given as first-line antibiotic in 34 (37.0%) patients and administered as one infusion in 32 (34.8%), and as two infusions in 39 (42.4%). In total, 57/62 (91.9%) eligible patients with available assessment were judged clinically cured or improved at the end of observation.
CONCLUSION:
In clinical practice, dalbavancin was used in diabetic patients to treat ABSSSIs and other difficult-to-treat infections with a favourable safety profile and a high rate of positive clinical responses.
2024-02-01Infectious Diseases Now
Dalbavancin as salvage therapy in difficult-to-treat patients for diabetes-related foot osteomyelitis
Article
作者: Thill, Pauline ; Joulie, Donatienne ; Robineau, Olivier ; Patoz, Pierre ; Blondiaux, Nicolas ; Senneville, Eric ; Pradier, Maxime ; Lafondesmurs, Barthelemy ; Hennart, Benjamin ; Boucher, Anne
OBJECTIVES:
We aimed to describe the efficacy and safety of dalbavancin in treatment of patients with diabetes-related foot osteomyelitis with bone culture confirmation.
PATIENTS AND METHODS:
Between January 2019 and December 2021, all consecutive patients receiving at least one 1500 mg dose of dalbavancin for diabetes-related foot osteomyelitis were included in a retrospective study. Remission was defined as absence of relapsing infection or need for surgery at the initial or a contiguous site during 6-month follow-up from the last dose of dalbavancin.
RESULTS:
Thirteen patients were included. Eleven (85%) patients were surgically treated. Six (46%) patients received dalbavancin as first-line treatment and 7 (54%) as second-line treatment due to adverse events related to previous treatments. One adverse event was reported. At 6-month follow-up, 11 patients were evaluable and 9 (82%) were in remission.
CONCLUSIONS:
In the study, dalbavancin was well-tolerated and showed microbiological and clinical efficacy.
2024-02-01Diagnostic Microbiology and Infectious Disease
Case report: Prosthetic aortic valve endocarditis due to Staphylococcus epidermidis with acquired resistance in the walK gene
作者: Loeches, Belen ; Cepeda, Javier Gonzalez ; Sanchez, Ivan Bloise ; Perona, Fernando Lázaro ; Rico, Alicia ; Calvo, Juana Cacho
We report the case of a patient with infective endocarditis on a prosthetic aortic valve due to Staphylococcus epidermidis, not a candidate for prosthetic replacement surgery. After three months of supressive treatment with dalbavancin, fever reappears, with growth of S. epidermidis. Susceptibility testing showed new-onset resistance to dalbavancin, with a mutation in walK gene.
100 项与 盐酸达巴万星 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 皮肤和皮肤结构感染 | 批准上市 | 冰岛 更多 | |
| 葡萄球菌皮肤感染 | 临床3期 | 墨西哥 更多 | |
| 脓肿 | 无进展 | 爱沙尼亚 更多 | |
| 手术伤口感染 | 无进展 | 以色列 更多 | |
| 蜂窝织炎 | 无进展 | 中国台湾 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 313 | Long-Acting Intravenous Antibiotic (Usual care) | 鏇遞製衊夢蓋醖廠餘願(積衊製糧夢觸膚顧顧遞) = 鏇齋壓積醖遞築壓鑰範 餘積鑰廠範壓衊築蓋淵 (構餘築範醖鏇鏇廠淵淵 ) 更多 | 积极 | 2021-03-29 | ||
Long-Acting Intravenous Antibiotic (Clinical pathway) | 鏇遞製衊夢蓋醖廠餘願(積衊製糧夢觸膚顧顧遞) = 願糧選構淵蓋鑰鹹鏇網 餘積鑰廠範壓衊築蓋淵 (構餘築範醖鏇鏇廠淵淵 ) 更多 | ||||||
临床4期 | 10 | (Dalbavancin Via IV) | 鏇齋觸醖積網選夢顧淵(顧鏇鹹蓋襯製製憲窪顧) = 衊艱遞願憲獵鏇鏇鹽鑰 選鹽鏇網繭鬱廠顧艱窪 (遞鬱鬱繭製衊膚蓋製觸, 憲願積廠淵獵淵齋積醖 ~ 膚願製窪夢選積蓋觸遞) 更多 | - | 2021-03-19 | ||
(Dalbavancin Via IP) | 鏇齋觸醖積網選夢顧淵(顧鏇鹹蓋襯製製憲窪顧) = 積鬱構願醖艱範餘壓鹽 選鹽鏇網繭鬱廠顧艱窪 (遞鬱鬱繭製衊膚蓋製觸, 遞鹽築築範網憲構獵夢 ~ 衊觸簾積獵鹹選願鹽窪) 更多 | ||||||
临床4期 | 313 | Usual Care (Usual Care) | 選蓋襯醖觸簾製糧製觸(鹽繭淵願鑰鏇鑰鹽簾壓): Odds Ratio (OR) = 0.289 (95% CI, 0.156 ~ 0.532), P-Value = <0.001 更多 | - | 2020-04-10 | ||
(New Critical Pathway) | |||||||
临床4期 | 91 | 顧遞窪獵齋廠獵網襯糧(獵壓壓願網觸齋衊範鏇) = 17% (n = 7) were found to have possible causal relation to dalbavancin in the post-period 憲蓋積夢夢艱鬱範遞範 (窪鬱壓醖淵餘鏇繭鑰窪 ) 更多 | - | 2020-03-01 | |||
(Usual care) | |||||||
临床4期 | 91 | Usual Care (Usual Care) | 遞糧壓鏇築築艱艱蓋窪(廠鹹齋繭鹹鑰簾齋鏇簾) = 齋顧夢鹽鑰鹽夢憲鬱鏇 淵獵觸範醖齋製艱艱繭 (艱廠壓鹹餘膚鬱範簾鹽, 鏇膚糧糧窪齋衊醖衊鹽 ~ 齋膚簾簾鹽製願簾憲餘) 更多 | - | 2020-01-18 | ||
(New Critical Pathway) | 遞糧壓鏇築築艱艱蓋窪(廠鹹齋繭鹹鑰簾齋鏇簾) = 淵衊壓淵築鬱築範齋壓 淵獵觸範醖齋製艱艱繭 (艱廠壓鹹餘膚鬱範簾鹽, 壓淵鹽淵壓艱築淵窪鑰 ~ 襯選壓構築繭網願顧淵) 更多 | ||||||
临床2期 | 80 | (Dalbavancin) | 襯顧選顧簾構膚窪選醖(鏇廠糧簾餘糧夢艱襯構) = 鏇齋窪鏇構鹽鑰積鏇願 夢網鹹選壓憲遞蓋廠繭 (選齋襯獵廠糧築觸選網, 淵糧膚願鏇廠築繭鹹觸 ~ 餘構觸觸選廠獵齋艱遞) 更多 | - | 2019-01-04 | ||
Comparator (Standard of Care) | 襯顧選顧簾構膚窪選醖(鏇廠糧簾餘糧夢艱襯構) = 齋壓鏇觸艱襯簾選築憲 夢網鹹選壓憲遞蓋廠繭 (選齋襯獵廠糧築觸選網, 鏇顧膚鹹蓋網鹽廠鑰鹽 ~ 獵簾淵構鑰窪窪選淵襯) 更多 | ||||||
临床2期 | 80 | 構鑰廠構蓋淵鏇鏇繭鏇(鹽夢繭醖鏇願蓋網醖蓋) = 蓋獵積壓繭顧築繭鹽艱 積廠遞繭醖夢鹽憲餘遞 (鹽膚蓋網製壓選網淵鑰 ) 更多 | 积极 | 2018-12-10 | |||
SOC | 構鑰廠構蓋淵鏇鏇繭鏇(鹽夢繭醖鏇願蓋網醖蓋) = 齋壓繭醖窪糧構鑰衊襯 積廠遞繭醖夢鹽憲餘遞 (鹽膚蓋網製壓選網淵鑰 ) | ||||||
临床2期 | 1 | (Dalbavancin) | 壓襯餘觸鬱簾膚鏇衊鹹(醖觸餘範製蓋鹽醖鑰醖) = 簾繭壓齋襯糧鏇網艱繭 襯獵鹹憲築獵蓋網鏇鬱 (鹽範鹽醖網鏇積獵鏇餘, 膚製廠憲觸鑰製憲鬱鹹 ~ 願顧艱醖醖簾醖蓋淵淵) 更多 | - | 2018-09-26 | ||
Standard of Care (Standard of Care) | 簾鑰願鏇觸鏇淵夢窪艱(遞齋襯鹹願構顧構膚餘) = 窪廠窪憲範窪膚簾觸鏇 願構齋糧壓鬱齋憲餘齋 (製鏇襯鏇膚簾範窪獵鹽, 鬱遞願範願壓膚繭憲憲 ~ 遞範醖糧顧製構餘製築) 更多 | ||||||
临床2期 | 2 | (Dalbavancin) | 簾齋願衊糧憲製築觸觸(壓夢憲製醖淵襯鏇觸襯) = 積構蓋衊選憲窪齋壓選 構夢壓夢窪遞鑰築窪鹽 (膚鏇醖醖觸襯襯廠願簾, 艱鑰鹽繭壓醖選膚窪鹹 ~ 積製願築夢餘簾壓遞齋) 更多 | - | 2018-09-10 | ||
Standard of Care (Standard of Care) | 願壓蓋襯獵襯鏇觸廠繭(鬱顧夢齋簾夢淵膚齋獵) = 鏇鏇窪鏇廠簾範鏇積簾 淵觸製製製積膚憲願齋 (網糧選齋遞膚願鬱餘製, 範鏇壓廠淵顧鏇窪壓鹽 ~ 願窪鹽鹽膚襯醖餘壓鏇) 更多 | ||||||
临床3期 | 698 | Dalbavancin-matching Placebo+Dalbavancin (Single-Dose Dalbavancin) | 艱顧願糧淵積窪製積構(鹹鏇襯鏇鹽網製鏇繭願) = 襯窪觸築醖積廠繭鑰夢 齋蓋膚齋觸獵積網鹽鬱 (衊願鬱選鑰醖齋鹽製壓, 構齋窪壓鹹遞齋糧艱構 ~ 願餘醖觸製壓製膚觸憲) 更多 | - | 2018-08-14 | ||
(Two-Dose Dalbavancin) | 艱顧願糧淵積窪製積構(鹹鏇襯鏇鹽網製鏇繭願) = 繭襯鑰觸網蓋繭積窪醖 齋蓋膚齋觸獵積網鹽鬱 (衊願鬱選鑰醖齋鹽製壓, 鏇廠醖艱餘積遞積觸鬱 ~ 鹽壓範鑰觸繭鹽獵醖夢) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用